CAC Imaging Saves Lives But Insurers Won't Pay — Experts Demand Coverage
Leading cardiologists argue insurance refusal to cover coronary calcium scans leaves high-risk patients undiagnosed and preventable heart attacks unchecked.
Summary
Coronary artery calcium (CAC) imaging is a proven, guideline-recommended tool for detecting subclinical coronary artery disease before a heart attack or stroke occurs. Despite three decades of evidence and endorsement by major U.S. cardiovascular societies, most insurers classify CAC as a screening test rather than a diagnostic one — leaving patients to pay out of pocket. This expert consensus statement, authored by leading cardiologists from institutions including Stanford, Mount Sinai, and Cedars-Sinai, argues that CAC imaging meets the criteria of a diagnostic test when ordered for borderline- or intermediate-risk patients flagged by standard risk assessment. The authors call on payers and policymakers to align coverage with clinical guidelines, enabling physicians to personalize treatment intensity based on quantified disease burden.
Detailed Summary
Atherosclerotic cardiovascular disease remains the leading cause of death in the United States and worldwide. A critical challenge is that most patients experience no warning symptoms until a catastrophic event — heart attack or stroke — occurs. Earlier detection of subclinical coronary artery disease (CAD) offers a clear path to prevention, yet a major systemic barrier persists in the form of insurance non-coverage.
This expert consensus statement, published in JACC Cardiovascular Imaging, makes the case that coronary artery calcium (CAC) imaging should be classified and covered as a diagnostic test. CAC scanning uses low-dose CT to quantify calcified plaque in coronary arteries, providing a direct measure of subclinical atherosclerosis that predicts adverse cardiovascular outcomes beyond traditional risk factors such as hypertension, hyperlipidemia, smoking, and diabetes.
Current prevention guidelines from U.S. cardiovascular societies recommend CAC imaging for individuals in borderline- or intermediate-risk categories — after initial risk factor assessment — to guide treatment decisions. Despite this, most payers do not cover the test, forcing patients to pay out of pocket. The authors argue this creates a two-tiered system where underdiagnosis drives preventable hospitalizations and deaths, ultimately costing the healthcare system more than the scan itself.
The paper distinguishes CAC's diagnostic role — used selectively in at-risk individuals — from population-wide screening, deliberately setting aside the latter to strengthen the narrower, more actionable argument for coverage. The authors emphasize shared decision-making: once CAD severity is quantified, physicians can personalize statin therapy, aspirin use, and lifestyle interventions accordingly.
This is a consensus position paper rather than a new clinical trial, so its strength rests on synthesizing existing evidence rather than generating new data. Nonetheless, the authorship — spanning 19 prominent cardiovascular researchers — lends significant weight to the call for policy change.
Key Findings
- CAC imaging predicts adverse cardiovascular outcomes beyond traditional risk factors, supported by 30+ years of evidence.
- Major U.S. cardiovascular guidelines already recommend CAC for borderline- and intermediate-risk patients to guide treatment.
- Most insurers still classify CAC as unproven screening, requiring out-of-pocket payment and causing widespread underdiagnosis.
- Authors frame CAC as a diagnostic test — not universal screening — to build the strongest case for immediate insurance coverage.
- Covering CAC imaging enables physicians to personalize treatment intensity based on quantified coronary artery disease severity.
Methodology
This is an expert consensus and policy statement, not a primary clinical trial. The authors synthesize existing literature and guideline recommendations to argue for a reclassification of CAC imaging from screening to diagnostic use. No new patient data were collected or analyzed.
Study Limitations
As a consensus statement based on abstract-level access, no new efficacy or outcomes data are presented, limiting causal claims. The paper explicitly excludes population-wide screening rationale, narrowing its policy scope. Coverage recommendations may face resistance from payers who require randomized trial evidence of mortality benefit specific to the diagnostic — rather than screening — use case.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.